骨肉瘤患者化疗效果的综合评估
|
摘要
背景:骨肉瘤是来源于间叶组织最常见的儿童及青少年原发恶性骨肿瘤。30年前,骨肉瘤采用单纯手术治疗,大部分病人在1年内死亡,5年生存率不足20%。采用联合化疗以及手术的综合治疗后患者的5年生存率提高到60-70%。化疗成为提高骨肉瘤患者预后的关键因素。但是在联合化疗的引入取得了巨大的成功后,骨肉瘤患者的生存率没有得到进一步的提高,就诊时没有转移的患者5年生存率在60-70%,即仍有30-40%的患者对目前的化疗不敏感,就诊时就存在转移的患者5年生存率仅有20%左右。如何早期区分出这些高危患者成为各国学者研究的焦点。
目的:通过分析骨肉瘤患者临床、影像、病理等特点,找出影响骨肉瘤患者预后的相关因素。从而早期区分出高危患者,给予特殊的治疗。
方法:研究2003年6月至2007年6月间就诊于北京大学人民医院骨与软组织肿瘤治疗中心的72例原发初治无转移的四肢成骨肉瘤患者。对他们进行了术前化疗+手术切除+术后化疗的标准治疗。所有切除标本进行坏死率分析。术后继续对患者进行化疗并进行随访。
对临床、影像、病理三方面的多个因素进行观测。
观察的临床项目包括:患者的年龄、性别、身高、体重、血型、疾病部位、就诊时关节活动度、是否存在骨折、化疗前后的碱性磷酸酶水平、乳酸脱氢酶的水平、血沉、化疗后疼痛是否减轻、关节活动是否改善、皮温是否降低、顺铂的注入方式共16项指标。
观察的影像学项目包括:X线判断:病变成溶骨改变,化疗后边界是否清晰,骨外钙化是否增加。MRI判断:瘤周水肿是否减少,骨内T1、T2信号变化,骨外T1、T2信号变化,肿瘤化疗前的体积,化疗前后肿瘤的体积变化。共10项影像学指标。
观察的病理学项目包括:肿瘤亚型和肿瘤坏死率。
将上述临床、影像、病理因素与肿瘤坏死率和患者预后相比较。通过统计学方法找出相关的预后因素。先应用χ2检验进行单因素相关分析,得出各因素与肿瘤坏死率的关系,再应用logistic回归进行多因素分析,得出各因素与肿瘤坏死率的关系。应用Kaplan-meier生存分析,进行单因素生存分析,并应用log-rank检验判断各个因素与患者生存率的关系;再应用cox多因素生存分析筛选出与预后相关的因素。
结果:单因素分析:男性患者、化疗后肿瘤体积变小、肿瘤边界变清晰、骨外T2信号增强提示肿瘤坏死率高(P<0.05);多因素分析:化疗后体积变小,提示肿瘤坏死率高(P<0.05);单因素生存分析显示:化疗后碱性磷酸酶水平正常,骨外T2信号增高,肿瘤坏死率高,提示患者的生存率较高(P<0.05)。多因素生存分析提示:肿瘤坏死率高的患者生存率高(P<0.05)。
结论:肿瘤坏死率高则患者的预后较好,通过临床、影像等多项指标综合判断,可以间接预测肿瘤坏死率,推测患者的预后。
Background: Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. Years ago, all patients with osteosarcoma were treated by amputation but the cure rate was under 10% and almost all patients died within a year from diagnosis. Today, for localized osteosarcoma at onset treated in specialized bone tumour centres with pre- and postoperative chemotherapy associated with surgery, the percentage of patients cured varies between 60% and 70%. Surgery is conservative (limb salvage) in more than 90% of patients. Prognosis is more severe (cure rate about 30%) for tumours located in the axial skeleton and in patients with metastasis at onset and in patients with recurrent disease. Presurgical chemotherapy has been advocated for these patients because of putative improvement in event free survival (EFS). The advantages of systemic chemotherapy include early administration of systemic chemotherapy, shrinkage of primary tumor, and pathologic identification of risk groups. The theoretic disadvantage is that it exposes a large tumor burden to marginally effective chemotherapy. Thus, how to distinguish poor responders from good responders before the end of chemotherapy is very important. This research contribute to monitoring and evaluation the effect of chemotherapy in patients with osteosarcoma.
Objective:To determine the prognostic factors that influence survival of patients with nonmetastatic, high-grade, osteosarcoma of the extremities in China.
Materials and Methods:A homogeneous group of 72 patients treated at Peking University People’s Hospital Muscularskeletal tumor center between June 2003 and June 2007, were retrospectively evaluated in relation to gender, age, height, tumor site and size, blood type, serum levels of alkaline phosphatase, X-ray and MRI changes, histological response to preoperative treatment.
Results:Upon Univariate analysis, tumor necrosis was significantly related to gender, tumor volume change, tumor margin and T2 signal intensity of the extraosseous component of bone sarcomas. Multivariate analysis, tumor necrosis was only related to tumor volume change. Upon multivariate analysis, good histological response to treatment maintained independent prognostic values on the outcome of patients with nonmetastatic osteosarcoma of the extremities.
Conclusion:Event free survival (EFS) was related to the tumor necrosis, the level of alkaline phosphatase (AKP) and the change of T2 signal of the extraosseous component. Tumor necrosis was related to the volume change after preoperative chemotherapy. These factors must be considered when deciding risk-adapted treatments for osteosarcoma patients.
目的:通过分析骨肉瘤患者临床、影像、病理等特点,找出影响骨肉瘤患者预后的相关因素。从而早期区分出高危患者,给予特殊的治疗。
方法:研究2003年6月至2007年6月间就诊于北京大学人民医院骨与软组织肿瘤治疗中心的72例原发初治无转移的四肢成骨肉瘤患者。对他们进行了术前化疗+手术切除+术后化疗的标准治疗。所有切除标本进行坏死率分析。术后继续对患者进行化疗并进行随访。
对临床、影像、病理三方面的多个因素进行观测。
观察的临床项目包括:患者的年龄、性别、身高、体重、血型、疾病部位、就诊时关节活动度、是否存在骨折、化疗前后的碱性磷酸酶水平、乳酸脱氢酶的水平、血沉、化疗后疼痛是否减轻、关节活动是否改善、皮温是否降低、顺铂的注入方式共16项指标。
观察的影像学项目包括:X线判断:病变成溶骨改变,化疗后边界是否清晰,骨外钙化是否增加。MRI判断:瘤周水肿是否减少,骨内T1、T2信号变化,骨外T1、T2信号变化,肿瘤化疗前的体积,化疗前后肿瘤的体积变化。共10项影像学指标。
观察的病理学项目包括:肿瘤亚型和肿瘤坏死率。
将上述临床、影像、病理因素与肿瘤坏死率和患者预后相比较。通过统计学方法找出相关的预后因素。先应用χ2检验进行单因素相关分析,得出各因素与肿瘤坏死率的关系,再应用logistic回归进行多因素分析,得出各因素与肿瘤坏死率的关系。应用Kaplan-meier生存分析,进行单因素生存分析,并应用log-rank检验判断各个因素与患者生存率的关系;再应用cox多因素生存分析筛选出与预后相关的因素。
结果:单因素分析:男性患者、化疗后肿瘤体积变小、肿瘤边界变清晰、骨外T2信号增强提示肿瘤坏死率高(P<0.05);多因素分析:化疗后体积变小,提示肿瘤坏死率高(P<0.05);单因素生存分析显示:化疗后碱性磷酸酶水平正常,骨外T2信号增高,肿瘤坏死率高,提示患者的生存率较高(P<0.05)。多因素生存分析提示:肿瘤坏死率高的患者生存率高(P<0.05)。
结论:肿瘤坏死率高则患者的预后较好,通过临床、影像等多项指标综合判断,可以间接预测肿瘤坏死率,推测患者的预后。
Background: Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. Years ago, all patients with osteosarcoma were treated by amputation but the cure rate was under 10% and almost all patients died within a year from diagnosis. Today, for localized osteosarcoma at onset treated in specialized bone tumour centres with pre- and postoperative chemotherapy associated with surgery, the percentage of patients cured varies between 60% and 70%. Surgery is conservative (limb salvage) in more than 90% of patients. Prognosis is more severe (cure rate about 30%) for tumours located in the axial skeleton and in patients with metastasis at onset and in patients with recurrent disease. Presurgical chemotherapy has been advocated for these patients because of putative improvement in event free survival (EFS). The advantages of systemic chemotherapy include early administration of systemic chemotherapy, shrinkage of primary tumor, and pathologic identification of risk groups. The theoretic disadvantage is that it exposes a large tumor burden to marginally effective chemotherapy. Thus, how to distinguish poor responders from good responders before the end of chemotherapy is very important. This research contribute to monitoring and evaluation the effect of chemotherapy in patients with osteosarcoma.
Objective:To determine the prognostic factors that influence survival of patients with nonmetastatic, high-grade, osteosarcoma of the extremities in China.
Materials and Methods:A homogeneous group of 72 patients treated at Peking University People’s Hospital Muscularskeletal tumor center between June 2003 and June 2007, were retrospectively evaluated in relation to gender, age, height, tumor site and size, blood type, serum levels of alkaline phosphatase, X-ray and MRI changes, histological response to preoperative treatment.
Results:Upon Univariate analysis, tumor necrosis was significantly related to gender, tumor volume change, tumor margin and T2 signal intensity of the extraosseous component of bone sarcomas. Multivariate analysis, tumor necrosis was only related to tumor volume change. Upon multivariate analysis, good histological response to treatment maintained independent prognostic values on the outcome of patients with nonmetastatic osteosarcoma of the extremities.
Conclusion:Event free survival (EFS) was related to the tumor necrosis, the level of alkaline phosphatase (AKP) and the change of T2 signal of the extraosseous component. Tumor necrosis was related to the volume change after preoperative chemotherapy. These factors must be considered when deciding risk-adapted treatments for osteosarcoma patients.
引文
1 Hansen MF, Nellissery MJ, Bhatia P. Common mechanisms of osteosarcoma and Paget's disease. J Bone Miner Res, 1999,14 Suppl 2:39-44.
2 Ruggieri P, Sim FH, Bond JR, et al. Malignancies in fibrous dysplasia. Cancer, 1994,73:1411-24.
3 Brien WW, Salvati EA, Healey JH, et al. Osteogenic sarcoma arising in the area of a total hip replacement. A case report. J Bone Joint Surg Am, 1990,72:1097-9.
4 Wadayama B, Toguchida J, Shimizu T, et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res, 1994,54:3042-8.
5 Tsuchiya T, Sekine K, Hinohara S, et al. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet, 2000,120:91-8.
6 Wang LL. Biology of osteogenic sarcoma. Cancer journal (Sudbury, Mass.), 2005,11:294-305.
7 a comparison study of staging systems for bone sarcomas.
8 Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. 1980. Clin Orthop Relat Res, 2003:4-18.
9 Kawaguchi N, Ahmed AR, Matsumoto S, et al. The concept of curative margin in surgery for bone and soft tissue sarcoma. Clin Orthop Relat Res, 2004:165-72.
10 Rosen G, Murphy ML, Huvos AG, et al. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer, 1976,37:1-11.
11 Campanacci M, Bacci G, Bertoni F, et al. The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli. Cancer, 1981,48:1569-81.
12 Rosenburg SA, Chabner BA, Young RC, et al. Treatment of osteogenic sarcoma. I. Effect of adjuvant high-dose methotrexate after amputation. Cancer Treat Rep, 1979,63:739-51.
13 Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer, 1982,49:1221-30.
14 Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol, 2003,21:1574-80.
15 Rosen G, Tan C, Sanmaneechai A, et al. The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. Cancer, 1975,35:936-45.
16 Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer, 1979,43:2163-77.
17 Rosen G. Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience. Orthopedics, 1985,8:659-64.
18 Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol, 1998,16:2452-8.
19 Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol, 1984,2:617-24.
20 Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol, 1988,6:329-37.
21 Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol, 1998,9:893-9.
22 Bielack S, Kempf-Bielack B, Schwenzer D, et al. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients]. Klin Padiatr,1999,211:260-70.
23 Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer, 1990,65:2539-53.
24 Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer, 1993,72:3227-38.
25 Ferrari S, Mercuri M, Picci P, et al. Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori, 1999,85:458-64.
26 Bacci G, Ferrari S, Longhi A, et al. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol. J Chemother, 2001,13:93-9.
27 Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer, 2001,37:2030-9.
28 Bacci G, Forni C, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol, 2003,25:845-53.
29 Smeland S, Wiebe T, Bohling T, et al. Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience. Acta Orthop Scand Suppl, 2004,75:92-8.
30 Smeland S, Muller C, Alvegard TA, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur JCancer, 2003,39:488-94.
31 Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol, 2003,14:1126-34.
32 Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol, 1990,8:1988-97.
33 Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet, 1997,350:911-7.
34 Bramwell VH, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol, 1992,10:1579-91.
35 Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol, 2000,18:4016-27.
36 Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol, 2005,23:2004-11.
37 Bacci G, Longhi A, Fagioli F, et al. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer, 2005,41:2836-45.
38 Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer, 2006,106:1154-61.
39 Carsi B, Rock MG. Primary osteosarcoma in adults older than 40 years. Clin Orthop Relat Res, 2002:53-61.
40 Rytting M, Pearson P, Raymond AK, et al. Osteosarcoma in preadolescent patients. Clin Orthop Relat Res, 2000:39-50.
41 Bacci G, Ferrari S, Mercuri M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999. Acta Orthop, 2007,78:377-84.
42 Bacci G, Longhi A, Bertoni F, et al. Primary high-grade osteosarcoma: comparison between preadolescent and older patients. J Pediatr Hematol Oncol, 2005,27:129-34.
43 Petrilli AS, Gentil FC, Epelman S, et al. Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer, 1991,68:733-7.
44 Scranton PE Jr, DeCicco FA, Totten RS, et al. Prognostic factors in osteosarcoma. A review of 20 year's experience at the University of Pittsburgh Health Center Hospitals. Cancer, 1975,36:2179-91.
45 Withrow SJ, Powers BE, Straw RC, et al. Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop Relat Res, 1991:159-68.
46 Tjalma RA. Canine bone sarcoma: estimation of relative risk as a function of body size. J Natl Cancer Inst, 1966,36:1137-50.
47 Fraumeni JF Jr. Stature and malignant tumors of bone in childhood and adolescence. Cancer, 1967,20:967-73.
48 Longhi A, Pasini A, Cicognani A, et al. Height as a risk factor for osteosarcoma. J Pediatr Hematol Oncol, 2005,27:314-8.
49 Bacci G, Longhi A, Ferrari S, et al. Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol Rep, 2002,9:171-5.
50 Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol, 1996,14:848-58.
51 Holscher HC, Bloem JL, Vanel D, et al. Osteosarcoma: chemotherapy-inducedchanges at MR imaging. Radiology, 1992,182:839-44.
52 Shin KH, Moon SH, Suh JS, et al. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. Clin Orthop Relat Res, 2000:200-8.
53 Lawrence JA, Babyn PS, Chan HS, et al. Extremity osteosarcoma in childhood: prognostic value of radiologic imaging. Radiology, 1993,189:43-7.
54 van der Woude HJ, Bloem JL, Hogendoorn PC. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities. Skeletal Radiol, 1998,27:57-71.
55 Abudu A, Davies AM, Pynsent PB, et al. Tumour volume as a predictor of necrosis after chemotherapy in Ewing's sarcoma. J Bone Joint Surg Br, 1999,81:317-22.
56 Brisse H, Ollivier L, Edeline V, et al. Imaging of malignant tumours of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment. Pediatr Radiol, 2004,34:595-605.
57 Lawrence JA, Babyn PS, Chan HS, et al. Extremity osteosarcoma in childhood: prognostic value of radiologic imaging. Radiology, 1993,189:43-7.
58 Mercuri M, Capanna R, Manfrini M, et al. The management of malignant bone tumors in children and adolescents. Clin Orthop Relat Res, 1991:156-68.
59 Velez-Yanguas MC, Warrier RP. The evolution of chemotherapeutic agents for the treatment of pediatric musculoskeletal malignancies. Orthop Clin North Am, 1996,27:545-9.
60 Malawer MM, Chou LB. Prosthetic survival and clinical results with use of large-segment replacements in the treatment of high-grade bone sarcomas. J Bone Joint Surg Am, 1995,77:1154-65.
61 Picci P, Sangiorgi L, Bahamonde L, et al. Risk factors for local recurrences after limb-salvage surgery for high-grade osteosarcoma of the extremities. Ann Oncol, 1997,8:899-903.
62 Schima W, Amann G, Stiglbauer R, et al. Preoperative staging of osteosarcoma: efficacy of MR imaging in detecting joint involvement. AJR Am J Roentgenol, 1994,163:1171-5.
63 Abudu A, Sferopoulos NK, Tillman RM, et al. The surgical treatment and outcome of pathological fractures in localised osteosarcoma. J Bone Joint Surg Br, 1996,78:694-8.
64 Grimer RJ, Taminiau AM, Cannon SR. Surgical outcomes in osteosarcoma. J Bone Joint Surg Br, 2002,84:395-400.
65 Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol, 2002,20:776-90.
66 Mialou V, Philip T, Kalifa C, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience. Cancer, 2005,104:1100-9.
67 Matsuo T, Sugita T, Sato K, et al. Clinical outcomes of 54 pelvic osteosarcomas registered by Japanese musculoskeletal oncology group. Oncology, 2005,68:375-81.
68 Bentzen SM, Poulsen HS, Kaae S, et al. Prognostic factors in osteosarcomas. A regression analysis. Cancer, 1988,62:194-202.
69 Uribe-Botero G, Russell WO, Sutow WW, et al. Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54. Am J Clin Pathol, 1977,67:427-35.
70 Price CH. The prognosis of osteosarcoma. An analytical study. Br J Radiol, 1966,39:181-8.
71 Bacci G, Bertoni F, Longhi A, et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer, 2003,97:3068-75.
72 Hauben EI, Weeden S, Pringle J, et al. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer,2002,38:1218-25.
73 Mintz MB, Sowers R, Brown KM, et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res, 2005,65:1748-54.
74 Khanna C, Khan J, Nguyen P, et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res, 2001,61:3750-9.
75 Martin TA, Harrison G, Mansel RE, et al. The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol, 2003,46:165-86.
76 Makitie T, Carpen O, Vaheri A, et al. Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma. Invest Ophthalmol Vis Sci, 2001,42:2442-9.
77 Wan X, Mendoza A, Khanna C, et al. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res, 2005,65:2406-11.
78 Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med, 2004,10:182-6.
79 Gillette JM, Chan DC, Nielsen-Preiss SM. Annexin 2 expression is reduced in human osteosarcoma metastases. J Cell Biochem, 2004,92:820-32.
80 Balch C, Dedman JR. Annexins II and V inhibit cell migration. Exp Cell Res, 1997,237:259-63.
81 Bleul CC, Fuhlbrigge RC, Casasnovas JM, et al. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med, 1996,184:1101-9.
82 Libura J, Drukala J, Majka M, et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood, 2002,100:2597-606.
83 Taichman RS, Cooper C, Keller ET, et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res, 2002,62:1832-7.
84 Perissinotto E, Cavalloni G, Leone F, et al. Involvement of chemokine receptor
4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res, 2005,11:490-7.
85 Poulaki V, Mitsiades N, Romero ME, et al. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2. Cancer Res, 2001,61:4864-72.
86 Ivanov VN, Bhoumik A, Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene, 2003,22:3152-61.
87 Worth LL, Lafleur EA, Jia SF, et al. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep, 2002,9:823-7.
88 Lafleur EA, Koshkina NV, Stewart J, et al. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res, 2004,10:8114-9.
89 Hornicek FJ, Gebhardt MC, Wolfe MW, et al. P-glycoprotein levels predict poor outcome in patients with osteosarcoma. Clin Orthop Relat Res, 2000:11-7.
90 Serra M, Scotlandi K, Reverter-Branchat G, et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol, 2003,21:536-42.
91 Smith J, Heelan RT, Huvos AG, et al. Radiographic changes in primary osteogenic sarcoma following intensive chemotherapy. Radiological-pathological correlation in 63 patients. Radiology, 1982,143:355-60.
92 Holscher HC, Hermans J, Nooy MA, et al. Can conventional radiographs be used to monitor the effect of neoadjuvant chemotherapy in patients with osteogenic sarcoma?. Skeletal Radiol, 1996,25:19-24.
93 Kumpan W, Lechner G, Wittich GR, et al. The angiographic response of osteosarcoma following pre-operative chemotherapy. Skeletal Radiol, 1986,15:96-102.
94 Carrasco CH, Charnsangavej C, Raymond AK, et al. Osteosarcoma: angiographic assessment of response to preoperative chemotherapy. Radiology, 1989,170:839-42.
95 Lang P, Grampp S, Vahlensieck M, et al. Primary bone tumors: value of MRangiography for preoperative planning and monitoring response to chemotherapy. AJR Am J Roentgenol, 1995,165:135-42.
96 Mail JT, Cohen MD, Mirkin LD, et al. Response of osteosarcoma to preoperative intravenous high-dose methotrexate chemotherapy: CT evaluation. AJR Am J Roentgenol, 1985,144:89-93.
97 Shirkhoda A, Jaffe N, Wallace S, et al. Computed tomography of osteosarcoma after intraarterial chemotherapy. AJR Am J Roentgenol, 1985,144:95-9.
98 Bloem JL, Taminiau AH, Eulderink F, et al. Radiologic staging of primary bone sarcoma: MR imaging, scintigraphy, angiography, and CT correlated with pathologic examination. Radiology, 1988,169:805-10.
99 Pan G, Raymond AK, Carrasco CH, et al. Osteosarcoma: MR imaging after preoperative chemotherapy. Radiology, 1990,174:517-26.
100 Holscher HC, Bloem JL, Nooy MA, et al. The value of MR imaging in monitoring the effect of chemotherapy on bone sarcomas. AJR Am J Roentgenol, 1990,154:763-9.
101 Fletcher BD. Response of osteosarcoma and Ewing sarcoma to chemotherapy: imaging evaluation. AJR Am J Roentgenol, 1991,157:825-33.
102 张朝晖孟埈非等. 磁共振动态增强影像在骨肿瘤或瘤样病变及软组织肿瘤诊断中的应用.国外医学临床放射学分册, 1999,2:77-80
103 Dyke JP, Panicek DM, Healey JH, et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology, 2003,228:271-8.
104 Reddick WE, Wang S, Xiong X, et al. Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma. Cancer, 2001,91:2230-7.
105 Reddick WE, Bhargava R, Taylor JS, et al. Dynamic contrast-enhanced MR imaging evaluation of osteosarcoma response to neoadjuvant chemotherapy. J Magn Reson Imaging, 1995,5:689-94.
106 van der Woude HJ, Bloem JL, Verstraete KL, et al. Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging indetecting viable tumor before surgery. AJR Am J Roentgenol, 1995,165:593-8.
107 Fletcher BD, Hanna SL, Fairclough DL, et al. Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy. Radiology, 1992,184:243-8.
108 Lang P, Wendland MF, Saeed M, et al. Osteogenic sarcoma: noninvasive in vivo assessment of tumor necrosis with diffusion-weighted MR imaging. Radiology, 1998,206:227-35.
109 Zhou XJ, Leeds NE, McKinnon GC, et al. Characterization of benign and metastatic vertebral compression fractures with quantitative diffusion MR imaging. AJNR Am J Neuroradiol, 2002,23:165-70.
110 Uhl M, Saueressig U, Koehler G, et al. Evaluation of tumour necrosis during chemotherapy with diffusion-weighted MR imaging: preliminary results in osteosarcomas. Pediatr Radiol, 2006,36:1306-11.
111 Redmond OM, Bell E, Stack JP, et al. Tissue characterization and assessment of preoperative chemotherapeutic response in musculoskeletal tumors by in vivo
31P magnetic resonance spectroscopy. Magn Reson Med, 1992,27:226-37.
112 van der Woude HJ, Bloem JL, Schipper J, et al. Changes in tumor perfusion induced by chemotherapy in bone sarcomas: color Doppler flow imaging compared with contrast-enhanced MR imaging and three-phase bone scintigraphy. Radiology, 1994,191:421-31.
113 Fletcher BD. Response of osteosarcoma and Ewing sarcoma to chemotherapy: imaging evaluation. AJR Am J Roentgenol, 1991,157:825-33.
114 Ongolo-Zogo P, Thiesse P, Sau J, et al. Assessment of osteosarcoma response to neoadjuvant chemotherapy: comparative usefulness of dynamic gadolinium-enhanced spin-echo magnetic resonance imaging and technetium-99m skeletal angioscintigraphy. Eur Radiol, 1999,9:907-14.
115 Schulte M, Brecht-Krauss D, Werner M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med, 1999,40:1637-43.
116 Hawkins DS, Rajendran JG, Conrad EU 3rd, et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positronemission tomography. Cancer, 2002,94:3277-84.
117 Franzius C, Bielack S, Flege S, et al. Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med, 2002,43:1012-7.
118 van der Woude HJ, Bloem JL, van Oostayen JA, et al. Treatment of high-grade bone sarcomas with neoadjuvant chemotherapy: the utility of sequential color Doppler sonography in predicting histopathologic response. AJR Am J Roentgenol, 1995,165:125-33.
119 Glasser DB, Lane JM, Huvos AG, et al. Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer, 1992,69:698-708.
120 Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med, 1977,101:14-8.
121 Bacci G, Bertoni F, Longhi A, et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer, 2003,97:3068-75.
122 Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer, 1997,33:1725-31.
123 Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J Clin, 2004,54:208-36.
124 Kremer LC, van Dalen EC, Offringa M, et al. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol, 2002,13:503-12.
125 Geidel S, Garn M, Gravinghoff L, et al. [Cardiomyopathy after osteosarcoma treatment: a contribution to the cardiotoxicity of adriamycin]. Klin Padiatr, 1991,203:257-61.
126 Meadows AT, Baum E, Fossati-Bellani F, et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Oncol, 1985,3:532-8.
127 Aung L, Gorlick RG, Shi W, et al. Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience. Cancer, 2002,95:1728-34.
128 Longhi A, Macchiagodena M, Vitali G, et al. Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. J Pediatr Hematol Oncol, 2003,25:292-6.
129 Longhi A, Porcu E, Petracchi S, et al. Reproductive functions in female patients treated with adjuvant and neoadjuvant chemotherapy for localized osteosarcoma of the extremity. Cancer, 2000,89:1961-5.
130 Cvitkovic E. Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat Rev, 1998,24:265-81.
131 Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol, 2005,23:8845-52.
132 Arndt C, Morgenstern B, Hawkins D, et al. Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma. Med Pediatr Oncol, 1999,32:93-6.
133 Voute PA, Souhami RL, Nooij M, et al. A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI). Ann Oncol, 1999,10:1211-8.
134 Harris MB, Gieser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol, 1998,16:3641-8.
135 Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol, 2003,21:2011-8.
136 Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol, 2002,20:426-33.
137 Saeter G, Hoie J, Stenwig AE, et al. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer, 1995,75:1084-93.
138 Hopper KD, Moser RP Jr, Haseman DB, et al. Osteosarcomatosis. Radiology, 1990,175:233-9.
139 Longhi A, Fabbri N, Donati D, et al. Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases. J Chemother, 2001,13:324-30.
140 Martini N, Huvos AG, Mike V, et al. Multiple pulmonary resections in the treatment of osteogenic sarcoma. Ann Thorac Surg, 1971,12:271-80.
141 Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol, 2003,21:710-5.
142 Hawkins DS, Arndt CA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer, 2003,98:2447-56.
143 Kempf-Bielack B, Bielack SS, Jurgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol, 2005,23:559-68.
144 Tabone MD, Kalifa C, Rodary C, et al. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol, 1994,12:2614-20.
145 Pastorino U, Gasparini M, Tavecchio L, et al. The contribution of salvage surgery to the management of childhood osteosarcoma. J Clin Oncol, 1991,9:1357-62.
146 Bacci G, Ferrari S, Mercuri M, et al. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand, 1998,69:230-6.
147 Rodriguez-Galindo C, Shah N, McCarville MB, et al. Outcome after localrecurrence of osteosarcoma: the St. Jude Children's Research Hospital experience (1970-2000). Cancer, 2004,100:1928-35.
148 Grimer RJ, Sommerville S, Warnock D, et al. Management and outcome after local recurrence of osteosarcoma. Eur J Cancer, 2005,41:578-83.
149 Sauerbrey A, Bielack S, Kempf-Bielack B, et al. High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma. Bone Marrow Transplant, 2001,27:933-7.
150 Fagioli F, Aglietta M, Tienghi A, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol, 2002,20:2150-6.
151 DeLaney TF, Park L, Goldberg SI, et al. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys, 2005,61:492-8.
152 Anderson P. Samarium for osteoblastic bone metastases and osteosarcoma. Expert Opin Pharmacother, 2006,7:1475-86.
153 Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr, 2000,10:159-78.
154 O'Keefe RJ, Guise TA. Molecular mechanisms of bone metastasis and therapeutic implications. Clin Orthop Relat Res, 2003:S100-4.
155 Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer, 2003,97:779-84.
156 Heymann D, Ory B, Gouin F, et al. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med, 2004,10:337-43.
157 Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer, 2000,88:2961-78.
158 Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst, 2002,94:1458-68.
159 Evdokiou A, Labrinidis A, Bouralexis S, et al. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone, 2003,33:216-28.
160 Heymann D, Ory B, Blanchard F, et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone, 2005,37:74-86.
161 Theoleyre S, Wittrant Y, Tat SK, et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev, 2004,15:457-75.
162 Chirgwin JM, Mohammad KS, Guise TA. Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact, 2004,4:308-18.
163 Masucci G, Wersall P, Ragnhammar P, et al. Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother, 1989,29:288-92.
164 Edmonson JH, Long HJ, Kvols LK, et al. Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas?. Ann Oncol, 1997,8:637-41.
165 Anderson PM, Markovic SN, Sloan JA, et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res, 1999,5:2316-23.
166 Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol, 1999,17:2781-8.
167 Kleinerman ES, Gano JB, Johnston DA, et al. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol, 1995,18:93-9.
168 Jia SF, An T, Worth L, et al. Interferon-alpha enhances the sensitivity of human osteosarcoma cells to etoposide. J Interferon Cytokine Res, 1999,19:617-24.
169 Strander H, Bauer HC, Brosjo O, et al. Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol, 1995,34:877-80.
170 Nilsonne U, Brostrom LA, Aparisi T. Local tumour resection in interferon treated osteosarcoma patients. Ann Chir Gynaecol, 1995,84:63-70.
171 Edmonson JH, Long HJ, Frytak S, et al. Phase II study of recombinant alfa-2ainterferon in patients with advanced bone sarcomas. Cancer Treat Rep, 1987,71:747-8.
172 Luksch R, Perotti D, Cefalo G, et al. Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma. Tumori, 2003,89:263-8.
173 Liebau C, Roesel C, Schmidt S, et al. Immunotherapy by gene transfer with plasmids encoding IL-12/IL-18 is superior to IL-23/IL-18 gene transfer in a rat osteosarcoma model. Anticancer Res, 2004,24:2861-7.
174 Jia SF, Worth LL, Densmore CL, et al. Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clin Cancer Res, 2003,9:3462-8.
175 Duan X, Jia SF, Koshkina N, et al. Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer, 2006,106:1382-8.
176 Theoleyre S, Mori K, Cherrier B, et al. Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer, 2005,5:123.
177 Joyama S, Naka N, Tsukamoto Y, et al. Dendritic cell immunotherapy is effective for lung metastasis from murine osteosarcoma. Clin Orthop Relat Res, 2006,453:318-27.
178 Densmore CL, Kleinerman ES, Gautam A, et al. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther, 2001,8:619-27.
179 Nakase M, Inui M, Okumura K, et al. p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome. Mol Cancer Ther, 2005,4:625-31.
180 Song SU, Boyce FM. Combination treatment for osteosarcoma with baculoviral vector mediated gene therapy (p53) and chemotherapy (adriamycin). Exp Mol Med, 2001,33:46-53.
181 Sulzbacher I, Birner P, Trieb K, et al. Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virchows Arch, 2002,441:345-9.
182 Lee YH, Tokunaga T, Oshika Y, et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer, 1999,35:1089-93.
183 Kaya M, Wada T, Kawaguchi S, et al. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer, 2002,86:864-9.
184 Dutour A, Monteil J, Paraf F, et al. Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. Mol Ther, 2005,11:311-9.
185 Kappel CC, Velez-Yanguas MC, Hirschfeld S, et al. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res, 1994,54:2803-7.
186 Pinski J, Schally AV, Halmos G, et al. Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. Int J Cancer, 1996,65:870-4.
187 Mansky PJ, Liewehr DJ, Steinberg SM, et al. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. J Pediatr Hematol Oncol, 2002,24:440-6.
188 Friedman MA, Carter SK. The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol, 1972,4:482-510.
189 Shin, Kyoo-Ho MD *, Moon, Seong-Hwan MD *, Suh, Jin-Suck MD **, et al. Tumor Volume Change as a Predictor of hemotherapeutic Response in Osteosarcoma. Clinical Orthopaedics & Related Research, 2000,July:200-208.
2 Ruggieri P, Sim FH, Bond JR, et al. Malignancies in fibrous dysplasia. Cancer, 1994,73:1411-24.
3 Brien WW, Salvati EA, Healey JH, et al. Osteogenic sarcoma arising in the area of a total hip replacement. A case report. J Bone Joint Surg Am, 1990,72:1097-9.
4 Wadayama B, Toguchida J, Shimizu T, et al. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res, 1994,54:3042-8.
5 Tsuchiya T, Sekine K, Hinohara S, et al. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet, 2000,120:91-8.
6 Wang LL. Biology of osteogenic sarcoma. Cancer journal (Sudbury, Mass.), 2005,11:294-305.
7 a comparison study of staging systems for bone sarcomas.
8 Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. 1980. Clin Orthop Relat Res, 2003:4-18.
9 Kawaguchi N, Ahmed AR, Matsumoto S, et al. The concept of curative margin in surgery for bone and soft tissue sarcoma. Clin Orthop Relat Res, 2004:165-72.
10 Rosen G, Murphy ML, Huvos AG, et al. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer, 1976,37:1-11.
11 Campanacci M, Bacci G, Bertoni F, et al. The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli. Cancer, 1981,48:1569-81.
12 Rosenburg SA, Chabner BA, Young RC, et al. Treatment of osteogenic sarcoma. I. Effect of adjuvant high-dose methotrexate after amputation. Cancer Treat Rep, 1979,63:739-51.
13 Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer, 1982,49:1221-30.
14 Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol, 2003,21:1574-80.
15 Rosen G, Tan C, Sanmaneechai A, et al. The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. Cancer, 1975,35:936-45.
16 Rosen G, Marcove RC, Caparros B, et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer, 1979,43:2163-77.
17 Rosen G. Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a ten year experience. Orthopedics, 1985,8:659-64.
18 Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol, 1998,16:2452-8.
19 Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol, 1984,2:617-24.
20 Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol, 1988,6:329-37.
21 Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol, 1998,9:893-9.
22 Bielack S, Kempf-Bielack B, Schwenzer D, et al. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients]. Klin Padiatr,1999,211:260-70.
23 Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer, 1990,65:2539-53.
24 Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer, 1993,72:3227-38.
25 Ferrari S, Mercuri M, Picci P, et al. Nonmetastatic osteosarcoma of the extremity: results of a neoadjuvant chemotherapy protocol (IOR/OS-3) with high-dose methotrexate, intraarterial or intravenous cisplatin, doxorubicin, and salvage chemotherapy based on histologic tumor response. Tumori, 1999,85:458-64.
26 Bacci G, Ferrari S, Longhi A, et al. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol. J Chemother, 2001,13:93-9.
27 Bacci G, Briccoli A, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer, 2001,37:2030-9.
28 Bacci G, Forni C, Ferrari S, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of good histologic response to the primary tumor or improve the final outcome. J Pediatr Hematol Oncol, 2003,25:845-53.
29 Smeland S, Wiebe T, Bohling T, et al. Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience. Acta Orthop Scand Suppl, 2004,75:92-8.
30 Smeland S, Muller C, Alvegard TA, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur JCancer, 2003,39:488-94.
31 Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol, 2003,14:1126-34.
32 Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol, 1990,8:1988-97.
33 Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet, 1997,350:911-7.
34 Bramwell VH, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol, 1992,10:1579-91.
35 Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol, 2000,18:4016-27.
36 Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol, 2005,23:2004-11.
37 Bacci G, Longhi A, Fagioli F, et al. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer, 2005,41:2836-45.
38 Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer, 2006,106:1154-61.
39 Carsi B, Rock MG. Primary osteosarcoma in adults older than 40 years. Clin Orthop Relat Res, 2002:53-61.
40 Rytting M, Pearson P, Raymond AK, et al. Osteosarcoma in preadolescent patients. Clin Orthop Relat Res, 2000:39-50.
41 Bacci G, Ferrari S, Mercuri M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999. Acta Orthop, 2007,78:377-84.
42 Bacci G, Longhi A, Bertoni F, et al. Primary high-grade osteosarcoma: comparison between preadolescent and older patients. J Pediatr Hematol Oncol, 2005,27:129-34.
43 Petrilli AS, Gentil FC, Epelman S, et al. Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer, 1991,68:733-7.
44 Scranton PE Jr, DeCicco FA, Totten RS, et al. Prognostic factors in osteosarcoma. A review of 20 year's experience at the University of Pittsburgh Health Center Hospitals. Cancer, 1975,36:2179-91.
45 Withrow SJ, Powers BE, Straw RC, et al. Comparative aspects of osteosarcoma. Dog versus man. Clin Orthop Relat Res, 1991:159-68.
46 Tjalma RA. Canine bone sarcoma: estimation of relative risk as a function of body size. J Natl Cancer Inst, 1966,36:1137-50.
47 Fraumeni JF Jr. Stature and malignant tumors of bone in childhood and adolescence. Cancer, 1967,20:967-73.
48 Longhi A, Pasini A, Cicognani A, et al. Height as a risk factor for osteosarcoma. J Pediatr Hematol Oncol, 2005,27:314-8.
49 Bacci G, Longhi A, Ferrari S, et al. Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol Rep, 2002,9:171-5.
50 Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol, 1996,14:848-58.
51 Holscher HC, Bloem JL, Vanel D, et al. Osteosarcoma: chemotherapy-inducedchanges at MR imaging. Radiology, 1992,182:839-44.
52 Shin KH, Moon SH, Suh JS, et al. Tumor volume change as a predictor of chemotherapeutic response in osteosarcoma. Clin Orthop Relat Res, 2000:200-8.
53 Lawrence JA, Babyn PS, Chan HS, et al. Extremity osteosarcoma in childhood: prognostic value of radiologic imaging. Radiology, 1993,189:43-7.
54 van der Woude HJ, Bloem JL, Hogendoorn PC. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities. Skeletal Radiol, 1998,27:57-71.
55 Abudu A, Davies AM, Pynsent PB, et al. Tumour volume as a predictor of necrosis after chemotherapy in Ewing's sarcoma. J Bone Joint Surg Br, 1999,81:317-22.
56 Brisse H, Ollivier L, Edeline V, et al. Imaging of malignant tumours of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment. Pediatr Radiol, 2004,34:595-605.
57 Lawrence JA, Babyn PS, Chan HS, et al. Extremity osteosarcoma in childhood: prognostic value of radiologic imaging. Radiology, 1993,189:43-7.
58 Mercuri M, Capanna R, Manfrini M, et al. The management of malignant bone tumors in children and adolescents. Clin Orthop Relat Res, 1991:156-68.
59 Velez-Yanguas MC, Warrier RP. The evolution of chemotherapeutic agents for the treatment of pediatric musculoskeletal malignancies. Orthop Clin North Am, 1996,27:545-9.
60 Malawer MM, Chou LB. Prosthetic survival and clinical results with use of large-segment replacements in the treatment of high-grade bone sarcomas. J Bone Joint Surg Am, 1995,77:1154-65.
61 Picci P, Sangiorgi L, Bahamonde L, et al. Risk factors for local recurrences after limb-salvage surgery for high-grade osteosarcoma of the extremities. Ann Oncol, 1997,8:899-903.
62 Schima W, Amann G, Stiglbauer R, et al. Preoperative staging of osteosarcoma: efficacy of MR imaging in detecting joint involvement. AJR Am J Roentgenol, 1994,163:1171-5.
63 Abudu A, Sferopoulos NK, Tillman RM, et al. The surgical treatment and outcome of pathological fractures in localised osteosarcoma. J Bone Joint Surg Br, 1996,78:694-8.
64 Grimer RJ, Taminiau AM, Cannon SR. Surgical outcomes in osteosarcoma. J Bone Joint Surg Br, 2002,84:395-400.
65 Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol, 2002,20:776-90.
66 Mialou V, Philip T, Kalifa C, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome--the French pediatric experience. Cancer, 2005,104:1100-9.
67 Matsuo T, Sugita T, Sato K, et al. Clinical outcomes of 54 pelvic osteosarcomas registered by Japanese musculoskeletal oncology group. Oncology, 2005,68:375-81.
68 Bentzen SM, Poulsen HS, Kaae S, et al. Prognostic factors in osteosarcomas. A regression analysis. Cancer, 1988,62:194-202.
69 Uribe-Botero G, Russell WO, Sutow WW, et al. Primary osteosarcoma of bone. Clinicopathologic investigation of 243 cases, with necropsy studies in 54. Am J Clin Pathol, 1977,67:427-35.
70 Price CH. The prognosis of osteosarcoma. An analytical study. Br J Radiol, 1966,39:181-8.
71 Bacci G, Bertoni F, Longhi A, et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer, 2003,97:3068-75.
72 Hauben EI, Weeden S, Pringle J, et al. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer,2002,38:1218-25.
73 Mintz MB, Sowers R, Brown KM, et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res, 2005,65:1748-54.
74 Khanna C, Khan J, Nguyen P, et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res, 2001,61:3750-9.
75 Martin TA, Harrison G, Mansel RE, et al. The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol, 2003,46:165-86.
76 Makitie T, Carpen O, Vaheri A, et al. Ezrin as a prognostic indicator and its relationship to tumor characteristics in uveal malignant melanoma. Invest Ophthalmol Vis Sci, 2001,42:2442-9.
77 Wan X, Mendoza A, Khanna C, et al. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res, 2005,65:2406-11.
78 Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med, 2004,10:182-6.
79 Gillette JM, Chan DC, Nielsen-Preiss SM. Annexin 2 expression is reduced in human osteosarcoma metastases. J Cell Biochem, 2004,92:820-32.
80 Balch C, Dedman JR. Annexins II and V inhibit cell migration. Exp Cell Res, 1997,237:259-63.
81 Bleul CC, Fuhlbrigge RC, Casasnovas JM, et al. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med, 1996,184:1101-9.
82 Libura J, Drukala J, Majka M, et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood, 2002,100:2597-606.
83 Taichman RS, Cooper C, Keller ET, et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res, 2002,62:1832-7.
84 Perissinotto E, Cavalloni G, Leone F, et al. Involvement of chemokine receptor
4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res, 2005,11:490-7.
85 Poulaki V, Mitsiades N, Romero ME, et al. Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2. Cancer Res, 2001,61:4864-72.
86 Ivanov VN, Bhoumik A, Ronai Z. Death receptors and melanoma resistance to apoptosis. Oncogene, 2003,22:3152-61.
87 Worth LL, Lafleur EA, Jia SF, et al. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep, 2002,9:823-7.
88 Lafleur EA, Koshkina NV, Stewart J, et al. Increased Fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res, 2004,10:8114-9.
89 Hornicek FJ, Gebhardt MC, Wolfe MW, et al. P-glycoprotein levels predict poor outcome in patients with osteosarcoma. Clin Orthop Relat Res, 2000:11-7.
90 Serra M, Scotlandi K, Reverter-Branchat G, et al. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol, 2003,21:536-42.
91 Smith J, Heelan RT, Huvos AG, et al. Radiographic changes in primary osteogenic sarcoma following intensive chemotherapy. Radiological-pathological correlation in 63 patients. Radiology, 1982,143:355-60.
92 Holscher HC, Hermans J, Nooy MA, et al. Can conventional radiographs be used to monitor the effect of neoadjuvant chemotherapy in patients with osteogenic sarcoma?. Skeletal Radiol, 1996,25:19-24.
93 Kumpan W, Lechner G, Wittich GR, et al. The angiographic response of osteosarcoma following pre-operative chemotherapy. Skeletal Radiol, 1986,15:96-102.
94 Carrasco CH, Charnsangavej C, Raymond AK, et al. Osteosarcoma: angiographic assessment of response to preoperative chemotherapy. Radiology, 1989,170:839-42.
95 Lang P, Grampp S, Vahlensieck M, et al. Primary bone tumors: value of MRangiography for preoperative planning and monitoring response to chemotherapy. AJR Am J Roentgenol, 1995,165:135-42.
96 Mail JT, Cohen MD, Mirkin LD, et al. Response of osteosarcoma to preoperative intravenous high-dose methotrexate chemotherapy: CT evaluation. AJR Am J Roentgenol, 1985,144:89-93.
97 Shirkhoda A, Jaffe N, Wallace S, et al. Computed tomography of osteosarcoma after intraarterial chemotherapy. AJR Am J Roentgenol, 1985,144:95-9.
98 Bloem JL, Taminiau AH, Eulderink F, et al. Radiologic staging of primary bone sarcoma: MR imaging, scintigraphy, angiography, and CT correlated with pathologic examination. Radiology, 1988,169:805-10.
99 Pan G, Raymond AK, Carrasco CH, et al. Osteosarcoma: MR imaging after preoperative chemotherapy. Radiology, 1990,174:517-26.
100 Holscher HC, Bloem JL, Nooy MA, et al. The value of MR imaging in monitoring the effect of chemotherapy on bone sarcomas. AJR Am J Roentgenol, 1990,154:763-9.
101 Fletcher BD. Response of osteosarcoma and Ewing sarcoma to chemotherapy: imaging evaluation. AJR Am J Roentgenol, 1991,157:825-33.
102 张朝晖孟埈非等. 磁共振动态增强影像在骨肿瘤或瘤样病变及软组织肿瘤诊断中的应用.国外医学临床放射学分册, 1999,2:77-80
103 Dyke JP, Panicek DM, Healey JH, et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology, 2003,228:271-8.
104 Reddick WE, Wang S, Xiong X, et al. Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma. Cancer, 2001,91:2230-7.
105 Reddick WE, Bhargava R, Taylor JS, et al. Dynamic contrast-enhanced MR imaging evaluation of osteosarcoma response to neoadjuvant chemotherapy. J Magn Reson Imaging, 1995,5:689-94.
106 van der Woude HJ, Bloem JL, Verstraete KL, et al. Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging indetecting viable tumor before surgery. AJR Am J Roentgenol, 1995,165:593-8.
107 Fletcher BD, Hanna SL, Fairclough DL, et al. Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy. Radiology, 1992,184:243-8.
108 Lang P, Wendland MF, Saeed M, et al. Osteogenic sarcoma: noninvasive in vivo assessment of tumor necrosis with diffusion-weighted MR imaging. Radiology, 1998,206:227-35.
109 Zhou XJ, Leeds NE, McKinnon GC, et al. Characterization of benign and metastatic vertebral compression fractures with quantitative diffusion MR imaging. AJNR Am J Neuroradiol, 2002,23:165-70.
110 Uhl M, Saueressig U, Koehler G, et al. Evaluation of tumour necrosis during chemotherapy with diffusion-weighted MR imaging: preliminary results in osteosarcomas. Pediatr Radiol, 2006,36:1306-11.
111 Redmond OM, Bell E, Stack JP, et al. Tissue characterization and assessment of preoperative chemotherapeutic response in musculoskeletal tumors by in vivo
31P magnetic resonance spectroscopy. Magn Reson Med, 1992,27:226-37.
112 van der Woude HJ, Bloem JL, Schipper J, et al. Changes in tumor perfusion induced by chemotherapy in bone sarcomas: color Doppler flow imaging compared with contrast-enhanced MR imaging and three-phase bone scintigraphy. Radiology, 1994,191:421-31.
113 Fletcher BD. Response of osteosarcoma and Ewing sarcoma to chemotherapy: imaging evaluation. AJR Am J Roentgenol, 1991,157:825-33.
114 Ongolo-Zogo P, Thiesse P, Sau J, et al. Assessment of osteosarcoma response to neoadjuvant chemotherapy: comparative usefulness of dynamic gadolinium-enhanced spin-echo magnetic resonance imaging and technetium-99m skeletal angioscintigraphy. Eur Radiol, 1999,9:907-14.
115 Schulte M, Brecht-Krauss D, Werner M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med, 1999,40:1637-43.
116 Hawkins DS, Rajendran JG, Conrad EU 3rd, et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positronemission tomography. Cancer, 2002,94:3277-84.
117 Franzius C, Bielack S, Flege S, et al. Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med, 2002,43:1012-7.
118 van der Woude HJ, Bloem JL, van Oostayen JA, et al. Treatment of high-grade bone sarcomas with neoadjuvant chemotherapy: the utility of sequential color Doppler sonography in predicting histopathologic response. AJR Am J Roentgenol, 1995,165:125-33.
119 Glasser DB, Lane JM, Huvos AG, et al. Survival, prognosis, and therapeutic response in osteogenic sarcoma. The Memorial Hospital experience. Cancer, 1992,69:698-708.
120 Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med, 1977,101:14-8.
121 Bacci G, Bertoni F, Longhi A, et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer, 2003,97:3068-75.
122 Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer, 1997,33:1725-31.
123 Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J Clin, 2004,54:208-36.
124 Kremer LC, van Dalen EC, Offringa M, et al. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol, 2002,13:503-12.
125 Geidel S, Garn M, Gravinghoff L, et al. [Cardiomyopathy after osteosarcoma treatment: a contribution to the cardiotoxicity of adriamycin]. Klin Padiatr, 1991,203:257-61.
126 Meadows AT, Baum E, Fossati-Bellani F, et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Oncol, 1985,3:532-8.
127 Aung L, Gorlick RG, Shi W, et al. Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience. Cancer, 2002,95:1728-34.
128 Longhi A, Macchiagodena M, Vitali G, et al. Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. J Pediatr Hematol Oncol, 2003,25:292-6.
129 Longhi A, Porcu E, Petracchi S, et al. Reproductive functions in female patients treated with adjuvant and neoadjuvant chemotherapy for localized osteosarcoma of the extremity. Cancer, 2000,89:1961-5.
130 Cvitkovic E. Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat Rev, 1998,24:265-81.
131 Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol, 2005,23:8845-52.
132 Arndt C, Morgenstern B, Hawkins D, et al. Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma. Med Pediatr Oncol, 1999,32:93-6.
133 Voute PA, Souhami RL, Nooij M, et al. A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI). Ann Oncol, 1999,10:1211-8.
134 Harris MB, Gieser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol, 1998,16:3641-8.
135 Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol, 2003,21:2011-8.
136 Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol, 2002,20:426-33.
137 Saeter G, Hoie J, Stenwig AE, et al. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer, 1995,75:1084-93.
138 Hopper KD, Moser RP Jr, Haseman DB, et al. Osteosarcomatosis. Radiology, 1990,175:233-9.
139 Longhi A, Fabbri N, Donati D, et al. Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases. J Chemother, 2001,13:324-30.
140 Martini N, Huvos AG, Mike V, et al. Multiple pulmonary resections in the treatment of osteogenic sarcoma. Ann Thorac Surg, 1971,12:271-80.
141 Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol, 2003,21:710-5.
142 Hawkins DS, Arndt CA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer, 2003,98:2447-56.
143 Kempf-Bielack B, Bielack SS, Jurgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol, 2005,23:559-68.
144 Tabone MD, Kalifa C, Rodary C, et al. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol, 1994,12:2614-20.
145 Pastorino U, Gasparini M, Tavecchio L, et al. The contribution of salvage surgery to the management of childhood osteosarcoma. J Clin Oncol, 1991,9:1357-62.
146 Bacci G, Ferrari S, Mercuri M, et al. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand, 1998,69:230-6.
147 Rodriguez-Galindo C, Shah N, McCarville MB, et al. Outcome after localrecurrence of osteosarcoma: the St. Jude Children's Research Hospital experience (1970-2000). Cancer, 2004,100:1928-35.
148 Grimer RJ, Sommerville S, Warnock D, et al. Management and outcome after local recurrence of osteosarcoma. Eur J Cancer, 2005,41:578-83.
149 Sauerbrey A, Bielack S, Kempf-Bielack B, et al. High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma. Bone Marrow Transplant, 2001,27:933-7.
150 Fagioli F, Aglietta M, Tienghi A, et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian sarcoma group study. J Clin Oncol, 2002,20:2150-6.
151 DeLaney TF, Park L, Goldberg SI, et al. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys, 2005,61:492-8.
152 Anderson P. Samarium for osteoblastic bone metastases and osteosarcoma. Expert Opin Pharmacother, 2006,7:1475-86.
153 Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr, 2000,10:159-78.
154 O'Keefe RJ, Guise TA. Molecular mechanisms of bone metastasis and therapeutic implications. Clin Orthop Relat Res, 2003:S100-4.
155 Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer, 2003,97:779-84.
156 Heymann D, Ory B, Gouin F, et al. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med, 2004,10:337-43.
157 Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer, 2000,88:2961-78.
158 Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst, 2002,94:1458-68.
159 Evdokiou A, Labrinidis A, Bouralexis S, et al. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone, 2003,33:216-28.
160 Heymann D, Ory B, Blanchard F, et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone, 2005,37:74-86.
161 Theoleyre S, Wittrant Y, Tat SK, et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev, 2004,15:457-75.
162 Chirgwin JM, Mohammad KS, Guise TA. Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact, 2004,4:308-18.
163 Masucci G, Wersall P, Ragnhammar P, et al. Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother, 1989,29:288-92.
164 Edmonson JH, Long HJ, Kvols LK, et al. Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas?. Ann Oncol, 1997,8:637-41.
165 Anderson PM, Markovic SN, Sloan JA, et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res, 1999,5:2316-23.
166 Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol, 1999,17:2781-8.
167 Kleinerman ES, Gano JB, Johnston DA, et al. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol, 1995,18:93-9.
168 Jia SF, An T, Worth L, et al. Interferon-alpha enhances the sensitivity of human osteosarcoma cells to etoposide. J Interferon Cytokine Res, 1999,19:617-24.
169 Strander H, Bauer HC, Brosjo O, et al. Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol, 1995,34:877-80.
170 Nilsonne U, Brostrom LA, Aparisi T. Local tumour resection in interferon treated osteosarcoma patients. Ann Chir Gynaecol, 1995,84:63-70.
171 Edmonson JH, Long HJ, Frytak S, et al. Phase II study of recombinant alfa-2ainterferon in patients with advanced bone sarcomas. Cancer Treat Rep, 1987,71:747-8.
172 Luksch R, Perotti D, Cefalo G, et al. Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma. Tumori, 2003,89:263-8.
173 Liebau C, Roesel C, Schmidt S, et al. Immunotherapy by gene transfer with plasmids encoding IL-12/IL-18 is superior to IL-23/IL-18 gene transfer in a rat osteosarcoma model. Anticancer Res, 2004,24:2861-7.
174 Jia SF, Worth LL, Densmore CL, et al. Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clin Cancer Res, 2003,9:3462-8.
175 Duan X, Jia SF, Koshkina N, et al. Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer, 2006,106:1382-8.
176 Theoleyre S, Mori K, Cherrier B, et al. Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer, 2005,5:123.
177 Joyama S, Naka N, Tsukamoto Y, et al. Dendritic cell immunotherapy is effective for lung metastasis from murine osteosarcoma. Clin Orthop Relat Res, 2006,453:318-27.
178 Densmore CL, Kleinerman ES, Gautam A, et al. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther, 2001,8:619-27.
179 Nakase M, Inui M, Okumura K, et al. p53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome. Mol Cancer Ther, 2005,4:625-31.
180 Song SU, Boyce FM. Combination treatment for osteosarcoma with baculoviral vector mediated gene therapy (p53) and chemotherapy (adriamycin). Exp Mol Med, 2001,33:46-53.
181 Sulzbacher I, Birner P, Trieb K, et al. Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors. Virchows Arch, 2002,441:345-9.
182 Lee YH, Tokunaga T, Oshika Y, et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer, 1999,35:1089-93.
183 Kaya M, Wada T, Kawaguchi S, et al. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer, 2002,86:864-9.
184 Dutour A, Monteil J, Paraf F, et al. Endostatin cDNA/cationic liposome complexes as a promising therapy to prevent lung metastases in osteosarcoma: study in a human-like rat orthotopic tumor. Mol Ther, 2005,11:311-9.
185 Kappel CC, Velez-Yanguas MC, Hirschfeld S, et al. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res, 1994,54:2803-7.
186 Pinski J, Schally AV, Halmos G, et al. Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. Int J Cancer, 1996,65:870-4.
187 Mansky PJ, Liewehr DJ, Steinberg SM, et al. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. J Pediatr Hematol Oncol, 2002,24:440-6.
188 Friedman MA, Carter SK. The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol, 1972,4:482-510.
189 Shin, Kyoo-Ho MD *, Moon, Seong-Hwan MD *, Suh, Jin-Suck MD **, et al. Tumor Volume Change as a Predictor of hemotherapeutic Response in Osteosarcoma. Clinical Orthopaedics & Related Research, 2000,July:200-208.